188 related articles for article (PubMed ID: 17080765)
1. Adapting the sample size planning of a phase III trial based on phase II data.
Wang SJ; Hung HM; O'Neill RT
Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765
[TBL] [Abstract][Full Text] [Related]
2. Sample size planning for phase II trials based on success probabilities for phase III.
Götte H; Schüler A; Kirchner M; Kieser M
Pharm Stat; 2015; 14(6):515-24. PubMed ID: 26412484
[TBL] [Abstract][Full Text] [Related]
3. Adapting by calibration the sample size of a phase III trial on the basis of phase II data.
Martini DD
Pharm Stat; 2011; 10(2):89-95. PubMed ID: 20140977
[TBL] [Abstract][Full Text] [Related]
4. Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed.
Preussler S; Kieser M; Kirchner M
Biom J; 2019 Mar; 61(2):357-378. PubMed ID: 30182372
[TBL] [Abstract][Full Text] [Related]
5. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
De Ridder F
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
[TBL] [Abstract][Full Text] [Related]
6. Conservative sample size estimation in nonparametrics.
De Martini D
J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
[TBL] [Abstract][Full Text] [Related]
7. Optimal planning of phase II/III programs for clinical trials with multiple endpoints.
Kieser M; Kirchner M; Dölger E; Götte H
Pharm Stat; 2018 Sep; 17(5):437-457. PubMed ID: 29700949
[TBL] [Abstract][Full Text] [Related]
8. A modified varying-stage adaptive phase II/III clinical trial design.
Dong G; Vandemeulebroecke M
Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
[TBL] [Abstract][Full Text] [Related]
9. The inclusion of real world evidence in clinical development planning.
Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
[TBL] [Abstract][Full Text] [Related]
10. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
Stallard N
Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
[TBL] [Abstract][Full Text] [Related]
11. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
12. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
13. Utility-based optimization of phase II/III programs.
Kirchner M; Kieser M; Götte H; Schüler A
Stat Med; 2016 Jan; 35(2):305-16. PubMed ID: 26256550
[TBL] [Abstract][Full Text] [Related]
14. An optimal three-stage design for phase II clinical trials.
Ensign LG; Gehan EA; Kamen DS; Thall PF
Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
[TBL] [Abstract][Full Text] [Related]
15. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
16. Integrated phase II/III clinical trials in oncology: a case study.
Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
[TBL] [Abstract][Full Text] [Related]
17. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
18. A seamless phase II/III design with sample-size re-estimation.
Bischoff W; Miller F
J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
[TBL] [Abstract][Full Text] [Related]
19. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
Fazzari M; Heller G; Scher HI
Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
[TBL] [Abstract][Full Text] [Related]
20. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
Rufibach K; Heinzmann D; Monnet A
Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
